Humanized tau antibody

The humanized antibody of claim 10, or a functional fragment thereof, wherein

• a. the HCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO:
• 1, a CDR2 with the amino acid sequence shown in SEQ ID NO:
• 2, and a CDR3 with the amino acid sequence shown in SEQ ID NO:
• 3, and/or wherein the LCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO:
• 4, a CDR2 with the amino acid sequence shown in SEQ ID NO:
• 5, and a CDR3 with the amino acid sequence shown in SEQ ID NO:
• 6;
• or
• b. the HCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO:
• 1, a CDR2 with the amino acid sequence shown in SEQ ID NO:
• 2, and a CDR3 with the amino acid sequence shown in SEQ ID NO:
• 3, and/or wherein the LCVR comprises a CDR1 with the amino acid sequence shown in SEQ ID NO:
• 10, a CDR2 with the amino acid sequence shown in SEQ ID NO:
• 5, and a CDR3 with the amino acid sequence shown in SEQ ID NO:
• 6.

A humanized antibody, or a functional fragment thereof, which antibody recognizes and specifically binds to a phospho-epitope on a human Tau protein as shown in SEQ ID NO:

• 19 or on a fragment thereof, but does not bind to the corresponding unphosphorylated epitope and/or to non-related epitopes, wherein said epitope comprises Tau aa 404-411 with the requirement of a phosphorylated Ser at position 409 (pS409), wherein said antibody or antibody fragment comprises a
• a. first binding domain, particularly a binding domain of a Heavy Chain Variable Region (HCVR), which contains an amino acid sequence having at least 95% identity to the sequence shown in SEQ ID NO:
• 7, SEQ ID NO:
• 20, or SEQ ID NO:
• 21, and/or a second binding domain, particularly a binding domain of a Light Chain Variable Region (LCVR), which contains an amino acid sequence having at least 95% identity to the sequence shown in SEQ ID NO:
• 8;
• or a
• b. first binding domain, particularly a binding domain of a Heavy Chain Variable Region (HCVR), which contains an amino acid sequence having at least 95% identity to the sequence shown in SEQ ID NO:
• 7, SEQ ID NO:
• 20, or SEQ ID NO:
• 21, and/or a second binding domain, particularly a binding domain of a Light Chain Variable Region (LCVR), which contains an amino acid sequence having at least 95% identity to the sequence shown in SEQ ID NO:
• 9.